Masayuki Kubota1, Yutaka Hirayama, Naoki Okuyama. 1. Department of Pediatric Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-Dori, Niigata 951-8510, Japan. mkubota@med.niigata-u.ac.jp
Abstract
PURPOSE: Basic fibroblast growth factor (bFGF) is a newly identified recombinant agent that promotes wound healing through an augmented neovascularization. This study examined the effect of bFGF in the treatment of perianal abscesses. PATIENTS AND METHODS: Nine consecutive males with an average age of 5.1 months (1-9 months) who presented with perianal abscess in the past 2 years were treated with bFGF (Transfermin, Kaken Co., Ltd., Tokyo, Japan). Two or three sprays of bFGF were applied to the perianal abscess two times a day. RESULTS: All nine patients responded well to the bFGF treatment. Pus discharge and local swelling around the fistula subsided within a mean of 7.3 ± 1.9 days (1 SD) after the initiation of treatment. One case showed a mild relapse 7 months after treatment and the other developed a new lesion 1 month after treatment. However, these lesions also similarly disappeared after a second treatment with bFGF without a recurrence in the follow-up examinations at 11 and 10 months, respectively. The remaining seven cases have all done well without any recurrence at a mean follow-up period of 14.1 ± 3.2 months. CONCLUSION: These results clearly indicate the usefulness of the bFGF spray as a new treatment strategy for the management of perianal abscesses.
PURPOSE:Basic fibroblast growth factor (bFGF) is a newly identified recombinant agent that promotes wound healing through an augmented neovascularization. This study examined the effect of bFGF in the treatment of perianal abscesses. PATIENTS AND METHODS: Nine consecutive males with an average age of 5.1 months (1-9 months) who presented with perianal abscess in the past 2 years were treated with bFGF (Transfermin, Kaken Co., Ltd., Tokyo, Japan). Two or three sprays of bFGF were applied to the perianal abscess two times a day. RESULTS: All nine patients responded well to the bFGF treatment. Pus discharge and local swelling around the fistula subsided within a mean of 7.3 ± 1.9 days (1 SD) after the initiation of treatment. One case showed a mild relapse 7 months after treatment and the other developed a new lesion 1 month after treatment. However, these lesions also similarly disappeared after a second treatment with bFGF without a recurrence in the follow-up examinations at 11 and 10 months, respectively. The remaining seven cases have all done well without any recurrence at a mean follow-up period of 14.1 ± 3.2 months. CONCLUSION: These results clearly indicate the usefulness of the bFGF spray as a new treatment strategy for the management of perianal abscesses.
Authors: Jeremy Sugrue; Johan Nordenstam; Herand Abcarian; Amelia Bartholomew; Joel L Schwartz; Anders Mellgren; Philip J Tozer Journal: Tech Coloproctol Date: 2017-06-15 Impact factor: 3.781
Authors: Marcin Włodarczyk; Jakub Włodarczyk; Aleksandra Sobolewska-Włodarczyk; Radzisław Trzciński; Łukasz Dziki; Jakub Fichna Journal: J Int Med Res Date: 2021-02 Impact factor: 1.671